What is CosmosID?
Founded in 2008 and headquartered in Rockville, Maryland, CosmosID operates at the intersection of bioinformatics and molecular diagnostics. The company provides a comprehensive, end-to-end microbiome platform designed to facilitate the identification and characterization of microorganisms. Its utility spans a wide array of high-stakes sectors, including pharmaceutical R&D, public health, food safety, agriculture, and environmental monitoring. By leveraging advanced computational pipelines, CosmosID enables researchers and clinicians to derive actionable insights from complex microbial data, effectively bridging the gap between raw sequencing output and clinical or industrial application.
How much funding has CosmosID raised?
CosmosID has raised a total of $7.5M across 3 funding rounds:
Series A
$1.3M
Series B
$6M
Debt
$150K
Series A (2011): $1.3M, investors not publicly disclosed
Series B (2016): $6M led by Applied Value Group
Debt (2020): $150K supported by PPP
Key Investors in CosmosID
Applied Value Group
Applied Value Group is a boutique investment, management consulting, and social impact firm with a global presence, focusing on ROI and capital productivity for its portfolio companies.
Undisclosed Investor
An undisclosed institutional participant involved in the company's historical financing rounds.
PPP
Public-Private Partnership
What's next for CosmosID?
With the recent influx of capital, CosmosID is well-positioned to accelerate its enterprise-level expansion. The strategic focus will likely center on enhancing the scalability of its bioinformatics platform and deepening its penetration into the pharmaceutical R&D market. As the global emphasis on microbiome-related therapeutics and diagnostics intensifies, the company is expected to leverage its technological moat to secure further market share. Future growth will likely be driven by the integration of machine learning models to further refine microbial identification accuracy, alongside potential partnerships aimed at standardizing microbiome analysis protocols in clinical and regulatory environments.
See full CosmosID company page
